Lydie Renault

Exciting news! Please tune in to this panel discussion on tackling AMR at Swiss Biotech Day, with esteemed experts coming together to address this critical global challenge and discuss actionable steps for the fight against AMR.

4

🥐 De bonnes nouvelles pour la #France ce matin! 🥐 💊 Leading pharmaceutical companies like Sanofi, GSK, Pfizer, and AbbVie are making substantial investments in R&D, clinical research, and drug production in northern France. 🔬 These initiatives are expected to generate over 800 new #jobs between 2024 and 2026 and produce top-tier #pharmaceuticals. 💲 Sanofi's commitment alone, with over 1 billion euros earmarked for expanding manufacturing capacity and constructing a new facility in Vitry-sur-Seine, highlights the region's emergence as a hub for innovation in healthcare. 📈 The investments not only foster economic growth but also underscore the companies' dedication to advancing healthcare solutions and creating opportunities for skilled professionals. https://lnkd.in/d6SWTUwa

20

When we founded Lead Candidate we were very clear that our vision was much more than #talentacquisition and was to create a mutually beneficial ecosystem 🌍 for the #pharma services sector 🧑‍🤝‍🧑🧪 Part of that commitment is to promote #people #businesses #tools that can play a positive role in the sector. That's why when Bernardo Estupiñán Gaisbauer talked me through his ambition for CDMO Advisor I knew we had to help get his message out. CDMO Advisor is a free tool that allows users to match their project needs to the right Service Providers on the platform, and puts them in direct contact. What traditionally takes hours of research, conversations and networking literally takes minutes! Check out the link below ⬇️ to learn more and if you're a service provider, get subscribed now! #cdmo #community #ecosystem #partnerships Lead Candidate

18

1 Kommentar

ASPHALION | REGULATORY AFFAIRS SUMMER QUIZ☀    🔝 Test your Regulatory knowledge!!    🔹 The summer is back and, for a 4th year in a row, so is ASPHALION’s classic #ASPHAQUIZ, our daily quiz to see how much our followers know about Regulatory Affairs. 😊    🔹The results of today´s poll 📊 will be published tomorrow.     🔹We hope you will enjoy it! Do not hesitate to share ⏩, comment 📣 and participate☑️!!    ▶ First question in the next post at 9:00! Stay tuned!!      #RegulatoryAffairs #QUIZ #ASPHAQUIZ #SUMMERQUIZ #SUMMERTIME #WeAreAsphalion #WeCare #KnowledgeFromExperience 

9

I was looking back at my photos today and saw a picture of our Q3 incentive, when we joined our German colleagues at Oktoberfest, reminding me of the great people I work with. At i-Pharm Consulting, we believe a unified culture drives long-term success. Here are some crazy important statistics to consider when creating your recruitment strategy. The costs of a poor culture fit are high - lower engagement, higher turnover, and diminished morale/productivity. A Columbia study found 88% of hiring failures stem from poor fit rather than lack of skills. Prioritizing culture fit is crucial, as SHRM research shows 46% of hires fail within 18 months when it's not a focus. As a recruiter, I know skills aren't everything. The right culture fit can make or break even the most talented hire. That's why I thoroughly evaluate how a candidate will integrate with my client's team dynamics and values before presenting them. When assessing candidates, I look at passion alignment, communication styles, behavioural traits, and check references to understand their fit at prior organizations. While technical expertise is essential, I support hiring those who can thrive within the established culture. A strong culture fit creates employees invested in the company's mission who collaborate effectively. Combined with the right skills, it leads to engaged, high-performing, and successful long-term hires. Gallup research found that companies with engaged workforces outperform their peers by 147% in earnings per share. Now that is something to consider! If cultural fit is something you have struggled with when hiring, reach out to me for a conversation on the below. I am always happy to discuss our strategy. Phone: +1 332-219-0879 or +44 02075510728 Email: ncrowley@i-pharmconsulting.com

27

11 Kommentare

🌍 Exciting Developments in Pharma Construction Across Europe! 🏗️ The pharmaceutical industry in Europe is buzzing with activity as several major new construction projects are taking shape. These infrastructure developments are not just about expanding production capacities but about driving innovation and ensuring resilience in our supply chains. From cutting-edge research facilities to state-of-the-art manufacturing plants, it's an exciting time for the sector. In the UK, plans are underway for a £300 million pharma campus in Manchester, which aims to become a global hub for research and pharmaceuticals. This ambitious project is expected to create over 3,000 jobs and significantly boost the local economy. Elsewhere, Germany continues to bolster its position with the development of a new €500 million facility in Berlin, set to enhance biopharmaceutical production capabilities by 2025. These projects underscore a broader European commitment to maintaining leadership in pharmaceuticals through strategic investment. These developments don't just benefit the industry; they positively impact various stakeholders, from research scientists and construction workers to local communities and healthcare providers. As someone passionate about both construction and pharmaceuticals, I find it inspiring to see such synergy driving progress and innovation. What are your thoughts on these exciting developments? How do you think they'll shape the future of healthcare in Europe? Let's discuss! 👇 #PharmaConstruction #InnovationInEurope #FutureOfHealthcare

5

Super helpful guide on French data sources and how to leverage these for those looking to plan evidence generation activities in the region

19

🌟 Discover the Swiss Biotech Revolution! Switzerland isn't just about chocolates and stunning landscapes—it's a powerhouse of biotech innovation! 🚀 From groundbreaking cancer treatments to regenerative medicine, Swiss startups are leading the charge. Dive into this latest article featuring 18 Swiss biotech companies that are transforming the future of healthcare. 🌍💉 #rare #raredisease #rarediseases #healthcare #biotech #pharma #pharmaceuticals #Switzerland #lifescience

10

From 6 to 9 June, we await an important date with the #EuropeanElections, where the 720 members of the Parliament will be elected. An event of vital importance for the citizens of the European Union, where they will be able to take part in the crucial decisions for the future of the continent.    The world needs a stronger and more united Europe and, at Merck Healthcare, we want to contribute to its economic and social empowerment through science, technology, and sustainability. To achieve this, we must ensure Merck in Europe has a much stronger, consistent, and more united voice for the world.   We face several challenges and priority areas on the EU policy agenda where we have the opportunity to position itself as part of the solution. In addition, the connection between Merck and Europe is getting stronger through our 28,000 employees dedicated to driving innovation with our headquarters in the heart of the continent.   It is #TimeToVote to reaffirm our role in the future and ensure a more united and global Europe.   #FromEuropeToGlobal  #MerckEU  

138

Sanofi reports that it has invested more than €1 billion ($1.1 billion) in Bioproduction in France across 3 sites! The new investment is expected to create more than 500 jobs and strengthen France’s ability to control the production of essential medicines from start to finish, currently and into the future, according to the company. The company will invest €1 billion to build a new facility in Vitry-sur-Seine that will double the site’s monoclonal antibody production capacity. Several biologics in development, including those for chronic obstructive pulmonary disorder (COPD), asthma, multiple sclerosis, and type 1 diabetes, could be produced in Vitry. At the Le Trait site in Normandy, Sanofi will invest €100 million ($109 million) to develop new capacity for biologics formulation, filling, device assembly and packaging. It will support the launch of future biologics and vaccines, as well as for the growth of Dupixent®, which already is indicated in several inflammatory diseases and could soon become the first biologic indicated in COPD, notes a Sanofi official. In Lyon Gerland, Sanofi is investing €10 million ($10.9 million) to locate the production of TZield® in France. Tzield is a biologic for type 1 diabetes that Sanofi acquired in April 2023 and which has been manufactured outside Europe. This plan brings to more than €3.5 billion ($3.8 billion) the amount committed by Sanofi since the COVID-19 pandemic in major projects to keep production of medicines and vaccines in France.

16

#Hypertension is a silent disease affecting millions worldwide. After the World Hypertension Day earlier this month, I wanted to emphasize the importance of awareness and action in combating this global health issue. At Servier, we are committed to advancing the prevention, diagnosis, and treatment of hypertension. For the past seven years, we have been dedicated to enhancing hypertension screening through our #BecauseISaySo global awareness campaign. This initiative aims to provide patients with the necessary information and tools to make regular blood pressure monitoring a habitual practice. Together, we can make a significant impact on reducing the burden of hypertension. #BeTheCaptainOfYourLife by #CheckYourBloodPressure regularly 💪 #BecauseIsayso Corina Jarquin Chems Eddine DJEGHLAL Liliana Alvarado Arévalo Michael van der Walt Caroline GIACOMONI (BELLAICHE) Anne VENOT Learn more here: https://lnkd.in/em5W7qBP

74

Gain firsthand experience from Parexel 's regulatory experts who have made over 250 EU-CTR applications, including almost 50 transition submissions. 📋 Our EU-CTR readiness can support you in navigating the requirements of this regulatory process successfully. Join us on April 30 for an insightful session! 🗓️ Further details and registration info linked below. #EUCTR #EURegulations #CTIS #EEA

5

🔔 Industry News: GSK Bets on Biosimilars with Sandoz Deal 🌟 GSK is making a strategic move into the biosimilars market through a collaboration with Sandoz, a Novartis division. This deal marks a significant step for GSK as it aims to expand its footprint in the competitive biosimilars space. 🌐 🔍 Key Highlights: -Strategic Partnership: GSK and Sandoz will work together to develop and commercialize biosimilar medicines, which are crucial for providing cost-effective alternatives to biologics. -Market Expansion: This collaboration positions GSK to tap into the growing biosimilars market, enhancing its portfolio and offering more treatment options to patients. -Healthcare Impact: By focusing on biosimilars, GSK aims to make high-quality, affordable medicines more accessible, potentially lowering healthcare costs and improving patient outcomes. This partnership underscores GSK’s commitment to innovation and affordability in healthcare. Stay tuned for more updates on this exciting development! 🚀 #GSK #Sandoz #Biosimilars #HealthcareInnovation #Pharmaceuticals #StrategicPartnership #Biologics #AffordableMedicine #PatientCare #IndustryNews

4

1 Kommentar

📣 In reality, rare diseases are anything but! Worldwide, they affect 260 to 450 million patients.   ⬇️ Nicolas Levy, physician and researcher in medical genetics and Chief Scientist Rare Diseases at Servier, explains the major challenges of research in rare diseases in the latest issue of Insights by Servier.   💪 At Servier, our goal is to meet patients’ medical needs and improve their quality of life. For example, we are focusing our R&D efforts on discovering new medicines that slow the progression of diseases with a genetic origin, which is the case for more than 80% of rare diseases.   Read Nicolas Levy’s full interview on rare diseases at 👉 https://lnkd.in/eBTC-jga   #WeAreServier #InsightsByServier #RareDiseases

147

Recently, I had breakfast with the president of a multinational pharmaceutical company in Latin America. He mentioned having difficulty finding the right talent. From our discussions, I gathered that he is looking for some essential characteristics in candidates: One highlighted trait was AMBITION and having the discipline to work harder than most. He also emphasized looking for individuals with the ENERGY to build a long-term career within the company. Lastly, he mentioned the importance of ENGAGEMENT WITH A LONG-TERM PROJECT THAT CAN ENRICH THEIR PROFESSIONAL CAREER. Having traveled to many countries, I see a significant demand in the market for this type of talent who is willing to commit. If you are a manager in need of such talent in Latin America or USA, Pacifica Continental, my recruitment business can assist you. Start receiving highly qualified candidates tailored to your industry: https://hubs.li/Q02zW5gK0

7

Learn about the unmet needs of people living with #PrimaryBiliaryCholangitis (PBC) and the advances in research that aim to improve liver health and quality of life. #MyCompany

3

338 days ago, a mere two weeks after joining a new industry and company, I found myself in the heart of Paris. The occasion? The inaugural Sanofi Global Employer Brand Workshop—a gathering of remarkable colleagues from around the world, all dedicated to amplifying Sanofi’s presence in the employment market and enable Sanofi to become the go-to employer in the bio-pharma. One of the buzzword during the workshops: “New Career Site.” Little did I know that this seemingly innocuous phrase would ignite a whirlwind of activity. A core project team materialized, and the countdown began. 300+ days ago: The RFP was launched—a pivotal moment that set the wheels in motion. 200+ days ago: After a rigorous selection process, we selected an agency that is one of the best in the game. 190+ days ago: Implementation kicked off. Late nights, countless meetings, and unwavering dedication fueled our progress. 38500 words: That’s how much we wrote, reviewed, and translated. Each word is a testament to our commitment. This project, probably one of the largest and most enduring I’ve been part of, pushed boundaries. But what’s truly miraculous? We’re not done. Phase 1 concluded today, and Phase 2 begins—an exciting continuation of our quest to redefine Sanofi’s employer brand. Stay tuned. The journey continues, and together, we’ll amplify Sanofi's presence in the employment market and enable Sanofi to become the go-to employer in bio-pharma - home of the best talent. One word, one line, one image, one frame, one video, one milestone at a time. See first-hand how you can help change lives and chase the miracles of science: -EN: https://jobs.sanofi.com/en -CN: https://jobs.sanofi.cn/ #SanofiStories #PursueProgress #DiscoverExtraordinary #赛诺菲中国 #No1TopEmployer #第一名中国杰出雇主 Audrey Clegg Rohit Joshi 李菲 Steffi Li Lynn Huang Daniel Perkins Florence PHILIPPOTEAUX Laura M. Pinkett, MBA Mary Todd Bergman Russell Weeks Katelyn Hunter Anne Adam Michele Pinna Maria Eugenia Viola Alen Evtimov Alexis Martin Vicky Yang

58

8 Kommentare

𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐭𝐡𝐚𝐭 𝐭𝐨𝐝𝐚𝐲, 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐲𝐨𝐮𝐧𝐠 𝐩𝐞𝐨𝐩𝐥𝐞, 𝐭𝐡𝐞 𝐰𝐨𝐫𝐝 '𝐒𝐢𝐜𝐤' 𝐢𝐬 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐚 𝐠𝐨𝐨𝐝 𝐭𝐡𝐢𝐧𝐠? Really, it is. It goes to show that not only are we, here at puretransfer.com, the people to give you high purity know-how, we're also the people to talk to if you need to know the latest 'hip lingo'. So, with that in mind we've put together some videos about our latest 'Sick' merchandise. 𝐇𝐚𝐯𝐞 𝐚 𝐰𝐚𝐭𝐜𝐡 (𝐭𝐡𝐞𝐲'𝐫𝐞 𝐣𝐮𝐬𝐭 𝐟𝐨𝐫 𝐟𝐮𝐧). #sick #merchandise #highpurity #puretransfer #funny https://lnkd.in/ew4avzjK

3

What does it mean to be all in on AI? 🔬 At Sanofi, we’re giving all of our employees access to better decision intelligence through “snackable AI” and doubling down on “expert” AI to help our R&D teams find the next breakthrough medicines and vaccines. To learn more about our ambition to become the first pharma company using AI at scale, see this clip with our own CEO, Paul Hudson, or watch the full interview here: http://spkl.io/611044UOUj #Technology #AI #ScienceAndTechnology

14

1 Kommentar